Clear Street’s Senti Biosciences Holdings SNTI Stock Holding History

Clear Street’s Portfolio SNTI Stock Details SNTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1	Closed	–	–	1233
2022 Q2	$0	Buy	+1	New	+$80	﹤0.01%	1045

Other funds holding SNTI

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Intel Corp Santa Clara, California $470M AUM 21.74% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Clear Street's SNTI Position: Q3 2022 in Review

Clear Street sold out of Senti Biosciences Holdings (SNTI) in Q3 2022, closing a stake of 1 share.

Clear Street first reported a position in SNTI in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 23 funds tracked by Wall St. Rank hold SNTI as of Q3 2022.

Clear Street reported no remaining Senti Biosciences Holdings position as of Q3 2022 after selling out during the quarter.
Clear Street sold 1 Senti Biosciences Holdings share in Q3 2022.
Clear Street first reported a position in Senti Biosciences Holdings in Q2 2022 and held it in 1 quarter.
Clear Street's Senti Biosciences Holdings position peaked at $0 in Q2 2022.
23 funds tracked by Wall St. Rank held Senti Biosciences Holdings as of Q3 2022.

Based on Clear Street's 13F filing for Q3 2022, filed 2 Nov 2022.